Search results for "Cytogenetics"

showing 10 items of 127 documents

Nucleoplasmic bridges and acrocentric chromosome associations as early markers of exposure to low levels of ionising radiation in occupationally expo…

2014

Ionising radiation, with the contribution of telomere shortening, induces DNA double-strand breaks that result in chromosome end fusion, nucleoplasmic bridges (NPBs) and chromosome aberrations (ChAbs) as well as dicentric chromosomes. In order to investigate the chromosomal damage induced by occupational ionising radiation at low exposure levels, and to find early markers of health hazard, peripheral lymphocytes of occupationally exposed hospital workers were cytogenetically analysed. Results showed a significant difference in the frequency of ChAbs in exposed subjects relative to controls. A significant number of NPBs between nuclei of binucleated cultured lymphocytes from exposed subjects…

AdultHealth Toxicology and MutagenesisLymphocyteBiologyToxicologyIonizing radiationAndrologyDicentric chromosomeOccupational ExposureRadiation IonizingCentromereGeneticsmedicineHumansLymphocytesIn Situ Hybridization FluorescenceGenetics (clinical)Cell NucleusChromosome AberrationsChromosomeEarly cytogenetics markers hospital workersMolecular biologyTelomereChromatinPersonnel HospitalSettore BIO/18 - GeneticaCell nucleusmedicine.anatomical_structureBiomarkersMutagenesis
researchProduct

Recombinations of chromosomal bands 10q24, 12q14-q15, and 14q24 in two cases of pulmonary chondroid hamartoma studied by fluorescence in situ hybridi…

2003

Abstract Pulmonary chondroid hamartomas (PCH) are benign mesenchymal tumors consisting of at least two cytogenetic subgroups. These subgroups are defined by chromosomal alterations at either 12q14∼q15 or 6p21. Cytogenetic analysis of short-term cultures from two PCHs revealed two different rearrangements with 12q14∼q15. One of these had a unique translocation t(12;14)(q14∼15;q24) with presence of two normal chromosomes 12 and a der(14), but missing the der(12). The other showed a complex rearrangement between chromosomes 10 and 12 with two different derivatives. Our data have been confirmed with fluorescence in situ hybridization analysis. These cases represent variant forms of the standard…

AdultLung DiseasesMaleCancer ResearchChromosomal Bandsmedicine.medical_specialtyChromosomal AlterationsHamartomaChromosomal translocationBiologyTranslocation GeneticGeneticsmedicineHamartomaHumansMolecular BiologyChromosome 12In Situ Hybridization FluorescenceGeneticsChromosomes Human Pair 14Chromosomes Human Pair 12medicine.diagnostic_testChromosomes Human Pair 10CytogeneticsMiddle Agedmedicine.diseaseMolecular biologyKaryotypingChondroid HamartomaFluorescence in situ hybridizationCancer genetics and cytogenetics
researchProduct

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

2014

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentOncogene Proteins FusionMicroarrayslcsh:MedicineLoss of HeterozygosityChromosomal translocationBiologyResearch and Analysis MethodsPolymorphism Single NucleotideTranslocation GeneticHematologic Cancers and Related DisordersLoss of heterozygosityYoung AdultLeukemia Promyelocytic AcuteLeukemiasGene duplicationMedicine and Health SciencesmedicineHumanslcsh:ScienceAgedChromosome AberrationsChromosomes Human Pair 15Multidisciplinarylcsh:RBreakpointCytogeneticsBiology and Life SciencesComputational BiologyHematologyMiddle AgedPrognosismedicine.diseaseMolecular biologyLeukemiaBioassays and Physiological AnalysisKaryotypingCancer researchlcsh:QFemaleResearch ArticleChromosomes Human Pair 17SNP arrayPLoS ONE
researchProduct

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

2003

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 c…

AdultMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticFusion Proteins bcr-ablAlpha interferonAntineoplastic AgentsBiologyGastroenterologyPiperazinesCytogeneticsRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProspective StudiesRNA MessengerneoplasmsInterferon alfaAgedHematologyABLCross-Over Studiesbreakpoint cluster regionCytarabineInterferon-alphaImatinibHematologyMiddle Agedmedicine.diseasePrognosisPyrimidinesTreatment OutcomeOncologyImmunologyBenzamidesCytarabineImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugLeukemia
researchProduct

Cytogenetic findings in secondary acute nonlymphocytic leukemia

1992

Abstract We here report the results of cytogenetic studies carried out in eight patients with acute nonlymphocytic leukemia developed after primary neoplasias. In seven of the reported cases, clonal chromosome aberrations were found, some being specific of de novo acute nonlymphocytic leukemia (ANLL). Numerical abnormalities were detected, such as the total monosomy of chromosomes 5, 7, 21, trisomy of chromosomes 8, 11, 15, and duplication of chromosome Y. Structural changes were also observed: a del(12)(p12), a del(16)(q22), the translocations t(3;5)(p21;q35),t(3;7)(p21;q35), and t(12;14)(p12;q32) and other changes involving chromosome 8. The finding of a hypertetraploid karyotype with com…

AdultMaleCancer Researchmedicine.medical_specialtyMonosomyChromosomal translocationBiologyTranslocation GeneticPolyploidyMonosomyhemic and lymphatic diseasesGeneticsmedicineHumansMolecular BiologyAgedChromosome AberrationsCytogeneticsChromosomeNeoplasms Second PrimaryKaryotypeMiddle Agedmedicine.diseaseLymphomaLeukemia Myeloid AcuteLeukemiaImmunologyCancer researchChromosomes Human Pair 5FemaleTrisomyChromosomes Human Pair 7Cancer Genetics and Cytogenetics
researchProduct

Chromosomal abnormalities in Waldenström's macroglobulinemia

1992

We report the results of cytogenetic studies of direct bone marrow (BM) preparations and of short-term BM and peripheral blood (PB) cultures from 17 patients with Waldenström's macroglobulinemia. We noted clonal chromosome changes in 10 patients. Abnormalities affected chromosomes X, Y, 2, 4, 5, 15, 16, 18, 19, 20, 21, and 22; in particular, chromosomes 2, 4, and 5 were involved in structural changes: a homogeneously staining region [hsr(2)], a der(4)t(4;?)(q32;?), and a 5q+. The other chromosomes were involved in numerical abnormalities, such as pseudodiploidy (a 46,X,-X,+15 clone), loss of chromosome Y, and monosomy of chromosomes 16, 18, 19, 20, 21, and 22. Nonclonal chromosome rearrange…

AdultMaleCancer Researchmedicine.medical_specialtyMonosomyClone (cell biology)Chromosome rearrangements Waldenström's macroglobulinemiaBiologyGeneticsmedicineHumanseducationMolecular BiologyHomogeneously Staining RegionAgedGeneticsAged 80 and overChromosome Aberrationseducation.field_of_studyCytogeneticsMacroglobulinemiaWaldenstrom macroglobulinemiaChromosomeKaryotypeMiddle Agedmedicine.diseaseMolecular biologySettore BIO/18 - GeneticaChromosomes Human Pair 2FemaleWaldenstrom Macroglobulinemia
researchProduct

Translocation (11;22) in small cell osteosarcoma

1990

AdultMaleOsteosarcomaCancer Researchmedicine.medical_specialtyLung NeoplasmsChromosomes Human Pair 11Chromosomes Human Pair 22CytogeneticsBone NeoplasmsKaryotypeChromosomal translocationBiologymedicine.diseaseMolecular biologyTranslocation GeneticSmall Cell OsteosarcomaScapulaKaryotypingGeneticsmedicineHumansOsteosarcomaMolecular BiologyCancer Genetics and Cytogenetics
researchProduct

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

2011

We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfavorable (-7/7q-) prognosis and also show that other sole or two abnormalities that do not include i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically aligned with normal karyotype, which is prognostically favorable. These findings were incorporated into a refined two-tired cytogenetic-risk stratification: unfavorable and favorable karyotype. The respective 5-y…

AdultMaleRiskCancer Researchmedicine.medical_specialtyPathologyAdolescentChromosomal translocationmyelofibrosisGastroenterologycytogeneticsDisease-Free SurvivalSettore MED/15 - Malattie Del SangueInternal medicineComplex KaryotypemedicineHumansMyelofibrosisAgedAged 80 and overChromosome AberrationsLeukemiaHematologyPlatelet Countbusiness.industryHazard ratioKaryotypeHematologyMiddle AgedPrognosismedicine.diseaseConfidence intervalkaryotypeOncologyPrimary MyelofibrosisInternational Prognostic Scoring SystemKaryotypingOriginal ArticleFemalemyeloproliferativebusiness
researchProduct

Two independent chromosomal rearrangements, a very small (550 kb) duplication of the 7q subtelomeric region and an atypical 17q11.2 <i>(NF1)&lt…

2006

Most patients with neurofibromatosis (NF1) are endowed with heterozygous mutations in the <i>NF1</i> gene. Approximately 5% show an interstitial deletion of chromosome 17q11.2 (including <i>NF1</i>) and in most cases also a more severe phenotype. Here we report on a 7-year-old girl with classical NF1 signs, and in addition mild overgrowth (97th percentile), relatively low OFC (10th–25th percentile), facial dysmorphy, hoarse voice, and developmental delay. FISH analysis revealed a 17q11.2 microdeletion as well as an unbalanced 7p;13q translocation leading to trisomy of the 7q36.3 subtelomeric region. The patient’s mother and grandmother who were phenotypically normal …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesNeurofibromatosesmedia_common.quotation_subjectBiologyCytogeneticsGene DuplicationGene duplicationGeneticsmedicineHumansGirlNeurofibromatosisneoplasmsMolecular BiologyGeneIn Situ Hybridization FluorescenceGenetics (clinical)Oligonucleotide Array Sequence AnalysisNeurofibromatosesmedia_commonGeneticsInfantChromosomeTelomereSubtelomeremedicine.diseaseeye diseasesnervous system diseasesChild PreschoolFemaleChromosome DeletionChromosomes Human Pair 7Chromosomes Human Pair 17Cytogenetic and Genome Research
researchProduct

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.

2017

Summary We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator-based assessment was 85·4%. Most patients (74%) underwent successful central laboratory-based molecular cytogenetic analysis. No clinically relevant differences in ORR post-induction were seen between patients with or without high-risk cytogenetic abnormalities (86·2% vs. 84·3%)…

AdultMalemedicine.medical_specialtyCyclophosphamideAdolescentPhases of clinical researchGastroenterologyRisk AssessmentTransplantation AutologousDexamethasoneBortezomib03 medical and health sciencesCytogeneticsYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectCyclophosphamideMultiple myelomaDexamethasoneBortezomibbusiness.industryHematologyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationConsolidation ChemotherapyRegimen030220 oncology & carcinogenesisFemalebusinessMultiple Myeloma030215 immunologymedicine.drugStem Cell TransplantationBritish journal of haematology
researchProduct